AB&B BIO-TECH-B (02627) announced its interim results for the six months ended June 30, 2025, reporting group revenue of RMB 71.123 million, representing a substantial increase of 919.25% year-on-year. The company recorded gross profit of RMB 60.781 million and research and development expenses of RMB 98.848 million.

Established in 2015, the company is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines using new technological approaches. The company's vaccine pipeline includes both innovative products that meet domestic demand and comply with global standards, as well as traditional vaccines utilizing new technological methods.

As of the announcement date, the company has two core products: the quadrivalent influenza virus subunit vaccine and the freeze-dried human rabies vaccine under development. The company also has 11 other vaccines in development, covering multiple disease areas with substantial vaccination needs. All of the company's vaccine products and products under development are currently or expected to be classified as Category II vaccines in China.

The company has established three comprehensive vaccine development support platforms: the genetic engineering and protein expression & purification platform, the mRNA vaccine research platform, and the adjuvant development & production platform, which enable the discovery and development of various categories of new vaccines. These are complemented by unique proprietary technology platforms, including the large-scale amplification platform, polysaccharide conjugation technology platform, and microbiology & immunology research platform, to further enhance the company's research and development capabilities.

As a result, as of June 30, 2025, the company has successfully obtained nine IND approvals for vaccines under development from the National Medical Products Administration.